〔Abstract〕Objective To investigate the effect of Haikun Shenxi capsule combined with benazepril on transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF) in the treatment of chronic renal failure(CRF). Methods A total of 120 patients with CRF admitted to Gongyi City People's Hospital from August 2016 to July 2018 were divided into observation group and control group by drawing lots, with 60 cases in each group. The control group was treated with benazepril, and the observation group was treated with Haikunshenxi capsule on the basis of the control group. The clinical efficacy, TGF-β1, CTGF levels and renal function indexes (serum creatinine, urea nitrogen) before and after treatment were compared between the two groups, and the incidence of adverse reactions during treatment were observed. Results The total effective rate of observation group was 86.7%, which was higher than 63.3% of the control group, and the difference was statistically significant (P < 0.05). After treatment, serum creatinine and urea nitrogen levels in the two groups were decreased compared with before treatment, and the observation group was significantly lower than that in the control group, the differences were statistically significant (P < 0.05). After treatment, the levels of serum TGF-β1 and CTGF in the two groups were decreased compared with before treatment, the observation group was significantly lower than taht in the control group, the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Compared with benazepril alone, Haikunshenxi capsule combined with benazepril in the treatment of CRF can achieve better efficacy, reduce the expression of TGF-β1 and CTGF, thereby improving renal fibrosis and delaying disease progression.